The anti-inflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta;Pravastatin ve nebivololün si{dotless}çan aortuna antienflamatuar ve antioksidan etkileri

Anadolu Kardiyoloji Dergisi

Volumn 14, Issue 3, 2014, Pages 229-233

  Dursun, Seyhun ^a   Çuhadar, Serap ^b   Köseoǧlu, Mehmet ^b   Atay, Ayşenur ^a   Aktaş, Safiye Günden ^c  

^a Chest Diseases Hospital   (Turkey)

^b Ataturk Research and Training State Hospital   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Atherosclerosis; Ceruloplasmin; Inflammation; Statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; N (G) NITROARGININE METHYL ESTER; NEBIVOLOL; PRAVASTATIN; UNCLASSIFIED DRUG; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CERULOPLASMIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; TRIACYLGLYCEROL; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ARTERY MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL INFILTRATION; CERULOPLASMIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; NONHUMAN; OXIDATIVE STRESS; RAT; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; URIC ACID BLOOD LEVEL; VASCULITIS; ANIMAL; AORTA; BLOOD; CHEMICALLY INDUCED; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; WISTAR RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; AORTA; CERULOPLASMIN; CHOLESTEROL; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; NEBIVOLOL; NG-NITROARGININE METHYL ESTER; PRAVASTATIN; RATS; RATS, WISTAR; TRIGLYCERIDES; URIC ACID;

EID: 84901715152     PISSN: 13028723     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.4708     Document Type: Article

References (37)

1. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-71. [CrossRef]
2. Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 2007; 48: 1800-15. [CrossRef]
3. Morales-Villegas EC, Di Sciascio G, Briguori C. Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins. Int J Hypertens 2011; 28; 2011: 904742.
4. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyagani S, Inoue S, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001; 89: 415-21. [CrossRef]
5. Davignon J. Atherosclerosis: Evolving vascular biology and clinical implications, beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III-39-III-43. [CrossRef]
6. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? J Am Coll Cardiol 2005; 46: 1855-62. [CrossRef]
7. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400. [CrossRef]
8. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36. [CrossRef]
9. Sasaki J, Otonari T, Uchida Y, Ikeda Y, Biro S, Kono S. Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT Study. J Atheroscler Thromb 2013; 20: 368-79. [CrossRef]
10. Asanuma Y, Oeser A, Stanley E, Bailey DG, Shintani A, Stein CM. Effects of C-reactive protein and homocysteine on cytokine production: modulation by pravastatin. Arch Drug Inf 2008; 1: 14-22. [CrossRef]
11. Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S, et al. Induction of endothelial nitric oxide synthase, SIRT 1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arteioscler Thromb Vasc Biol 2010; 30: 2205-11. [CrossRef]
12. Toblli JE, DiGennaro F, Giani JF, Dominici FP. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag 2012; 8: 151-60. [CrossRef]
13. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009; 54: 1491-9. [CrossRef]
14. Rozec B, Quang TT, Noireaud J, Gauthier C. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol 2006; 147: 699-706. [CrossRef]
15. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004; 43: 140-53. [CrossRef]
16. Çelik T, İyisoy A, Kurşakli{dotless}oǧlu H, Kardeşoǧlu E, Ki{dotless}li{dotless}ç S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-6. [CrossRef]
17. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro L J. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006; 15: 265-79. [CrossRef]
18. Vardi{dotless} N, Öztürk F, Fadi{dotless}lli{dotless}oǧlu E, Otlu A, Yaǧmurca M. Histological changes in the rat thoracic aorta after chronic nitric oxide synthase inhibition. Turk J Med Sci 2003; 33: 141-7.
19. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 277-85. [CrossRef]
21. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab 2004; 10: 1-15.
22. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000; 20: 1536-42. [CrossRef]
23. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 2000; 28: 1735-44. [CrossRef]
24. Patil N, Chavan V, Karnilk ND. Antioxidant status in patients with acute myocardial infarction. Indian J Clin Biochem 2007; 22: 45-51. [CrossRef]
25. Xu Y, Lin H, Zhou Y, Wang Y, Cheng G, Xu G. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostatis. Nat Chem Biol 2006; 2: 486-93. [CrossRef]
26. Carmine Z, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1460-71.
27. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 2001; 38: 1850-8. [CrossRef]
28. Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther 2013; 18: 13-8. [CrossRef]
29. López-Cuenca A, Roldán V, Marin F. Hypouricemic effect of statins: another pleiotropic benefit? J Thorac Cardiovasc Surg 2010; 139: 1358-9. [CrossRef]
30. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5. [CrossRef]
31. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519-30. [CrossRef]
32. Yoon SJ, Yoon YW, Lee BK, Kwon HM, Hwang KC, Kim M, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009; 41: 802-11. [CrossRef]
33. Büyükhatipoǧlu H, Sezen Y, Yi{dotless}ldi{dotless}z A, Güntekin U, Baş M, Polat M, et al. Effects of statin use on total antioxidant capacity and ceruloplasmin activity. Clin Invest Med 2010; 33: 313-20.
34. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1995; 1254: 7-12. [CrossRef]
35. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23: 615-21. [CrossRef]
36. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8: 127-34. [CrossRef]
37. Uzar E, Acar A, Evliyaoǧlu O, Fi{dotless}rat U, Kamasak K, Göçmez C, et al. The anti-oxidant and anti-apoptotic effects of nebivolol and zofenopril in a model of cerebral ischemia/reperfusion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 22-8. [CrossRef]